Paper
Organic & Biomolecular Chemistry
were washed once with PBS and the cell nuclei were stained
for 15 min with the permeable dye H33342 (2 µg ml−1 in PBS,
Sigma). H33342 was then removed by a final PBS wash. Images
(4 central sites per well) were acquired automatically on an IX
Ultra confocal platereader (Molecular Devices, Sunnyvale CA,
U.S.A.), equipped with a Plan Fluor 40× NA0.6 extra-long
working distance objective and 405 nm/488 nm laser lines for
H33342 and sfGFP excitation respectively.
References
1 K. Tatemoto, Proc. Natl. Acad. Sci. U. S. A., 1982, 79, 5485–
5489.
2 J. G. Wettstein, B. Earley and J. L. Junien, Pharmacol. Ther.,
1995, 65, 397–414.
3 S. P. Sheikh, Am. J. Physiol. Gastrointest. Liver Physiol., 1991,
261, G701–G715.
An automated granularity algorithm (MetaXpress 5.1, Mole-
cular Devices) identified internal fluorescent compartments
within these images of at least 3 µm diameter (range set to
3–18 µm). For each experiment, granules were classified on the
basis of intensity thresholds which were set manually with
reference to the negative (vehicle) or positive (1 µM NPY, or
100 nM PP) plate controls. The response for each data point
was quantified as mean granule average intensity per cell,
from assessment of 12 images (4 sites per well in triplicate),
normalised to the reference agonist response. Concentration
response curves were fitted to the pooled data by non-linear
least squares regression (Graphpad Prism), and antagonist pKb
values were calculated from agonist curve shifts using the
Gaddum equation (pKb = log[CR − 1] − log[B], where [B] is the
4 A. G. Blomqvist and H. Herzog, Trends Neurosci., 1998, 20,
294–298.
5 C. Cabrele and A. G. Beck-Sickinger, J. Pept. Sci., 2000, 6,
97–122.
6 M. Ruscica, E. Dozio, M. Motta and P. Magni, Curr. Top.
Med. Chem., 2007, 7, 1682–1691.
7 N. Sato, Y. Ogino, S. Mashiko and M. Ando, Expert Opin.
Ther. Pat., 2009, 19, 1401–1415.
8 R. C. Alfred Meurs, G. Ebinger, Y. Michotte and
I. Smolders, Curr. Top. Med. Chem., 2007, 7, 1660–
1674.
9 Y. Dumont, P. Gaudreau, M. Mazzuferi, D. Langlois,
J. G. Chabot, A. Fournier, M. Simonato and R. Quirion,
Br. J. Pharmacol., 2005, 146, 1069–1081.
antagonist concentration, and CR is the EC50 ratio for the 10 M. Keller, G. Bernhardt and A. Buschauer, ChemMedChem,
agonist response in the presence and absence of antagonist).
2011, 6, 1566–1571.
11 Y. Dumont, J.-A. St-Pierre and R. Quirion, NeuroReport,
1996, 7, 901–904.
Fluorescent imaging of compound VIII
12 H. N. Doods, H. A. Wieland, W. Engel, W. Eberlein,
K.-D. Willim, M. Entzeroth, W. Wienen and K. Rudolf,
Regul. Pept., 1996, 65, 71–77.
293TR Y1-GFP or Y4-GFP cells were seeded at 20 000 cells per
well in poly-D-lysine coated 96 well imaging plates (Greiner
655090), treated with 1 µg ml−1 tetracycline for 18–21 h and
then used in experiments at confluence. Cells were incubated
in HEPES-buffered saline solution (HBSS) including 0.1% BSA,
H33342 (2 µg ml−1) and varying concentrations of competitor
ligands (10−10 M to 10−6 M) for 2 min, prior to the addition of
compound VIII at a final concentration of 1 nM (Y1-GFP) or
100 nM (Y4-GFP). Incubations were continued for 30 min at
37 °C, after which the media was replaced with HBSS/0.1%
BSA (to remove free compound VIII). The cells were immedi-
ately imaged (2 sites per well) on a Molecular Devices IX Micro
epifluorescence platereader using excitation/emission filter
sets appropriate for H33342 (DAPI), Y receptor-GFP (FITC),
and the rhodamine ligand (TRITC). Read time was less than
10 min, and repeated “total” wells at the end of the read con-
firmed stable binding of the fluorescent ligand over this
period. Bound ligand fluorescence was quantified by granular-
ity analysis (2–3 µm diameter granules; count per cell using
MetaXpress), and normalised to positive (totals 100%) and
negative (0%, presence of 1 µM NPY) controls. NPY and
BIBO3304 IC50 values were then determined using Graphpad
Prism, as for radioligand binding.
13 A. Brennauer, S. Dove and A. Buschauer, Neuropeptide
Y
and related peptides, Springer, Berlin Heidelberg,
2004.
14 H. A. Wieland, W. Engel, W. Eberlein, K. Rudolf and
H. N. Doods, Br. J. Pharmacol., 1998, 125, 549–555.
15 C. Mollereau, H. Mazarguil, D. Marcus, I. Quelven,
M. Kotani, V. Lannoy, Y. Dumont, R. Quirion, M. Detheux,
M. Parmentier and J.-M. Zajac, Eur. J. Pharmacol., 2002,
451, 245–256.
16 J. J. Leban, D. Heyer, A. Landavazo, J. Matthews,
A. Aulabaugh and A. J. Daniels, J. Med. Chem., 1995, 38,
1150–1157.
17 A. Balasubramaniam, V. C. Dhawan, D. E. Mullins,
W. T. Chance, S. Sheriff, M. Guzzi, M. Prabhakaran and
E. M. Parker, J. Med. Chem., 2001, 44, 1479–1482.
18 E. M. Parker, C. K. Babij, A. Balasubramaniam,
R. E. Burrier, M. Guzzi, F. Hamud, G. Mukhopadhyay,
M. S. Rudinski, Z. Tao, M. Tice, L. Xia, D. E. Mullins and
B. G. Salisbury, Eur. J. Pharmacol., 1998, 349, 97–105.
19 D. Zwanziger, D. L. Ilka BÓ§hme and A. G. Beck-Sickinger,
J. Pept. Sci., 2009, 15, 856–866.
20 B. Guérin, V. Dumulon-Perreault, M.-C. Tremblay, S. Ait-
Mohand, P. Fournier, C. Dubuc, S. Authier and F. Bénard,
Bioorg. Med. Chem. Lett., 2010, 20, 950–953.
Acknowledgements
This work was supported by CRC for Biomedical Imaging 21 B. Guérin, S. Ait-Mohand, M.-C. Tremblay, V. Dumulon-
Development (CRC-BID), Australia. ML was supported by an
Australian Post-graduate Award scholarship.
Perreault, P. Fournier and F. Bénard, Org. Lett., 2010, 12,
280–283.
3280 | Org. Biomol. Chem., 2014, 12, 3271–3281
This journal is © The Royal Society of Chemistry 2014